A month after China publicly revealed its bioeconomy priorities under its 15th Five Year Plan, the European Commission released an updated EU Bioeconomy Strategy — and the contrast could hardly be sharper. While China bets on a bold mix of AI, bioengineering and synthetic biology to replace fossil based industrial products with recombinant and cell free systems, the EU remains anchored in a more traditional vision focused on the valorisation of agricultural output and industrial waste. By contrast, the UK has taken a more modern approach, heavily investing in engineering biology — the use of reprogrammed microorganisms to produce industrial goods — as a key pillar of its biotech and bioeconomy strategy.
Orano Med and Roche ink clincical distribution deal in radiopharmacy
Latest NewsOrano Med and Roche have launched a clinical development programme for CEA‑targeted two‑step PRIT using lead‑212, with Orano supplying the ²¹²Pb, while Novartis and ITM are expanding production of alpha‑emitting radiopharmaceuticals.
EU trilogue sets clear path for new genomic techniques
Latest NewsAfter four EU Council presidencies, EU member states and the European Parliament yesterday struck a provisional deal on new genomic techniques under the current Danish presidency, setting clear rules to boost agrifood innovation, plant resilience, transparency and sustainability.
Topical DHT blockade demonstrates significant efficacy
Latest NewsClascoterone 5% topical solution has demonstrated significant hair growth in Phase III trials, showing strong efficacy and a favourable safety profile in men with androgenetic alopecia.
UK hikes drug prices after pharma exodus
Latest NewsAfter the withdrawal of investment pledges totalling £2bn by pharmaceutical companies — seeking to offset lower US revenue by raising UK prices — the British government has now caved in and signed a deal with the US administration that will lift UK drug prices by 25%
Angelini Ventures and EIB launch joint start-up financing
Latest NewsThe European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed an agreement to jointly provide €150m over the next six years to support European biotechnology and digital health start-ups through seven to ten funding rounds. This marks the EIB’s first partnership with a corporate venture capital firm in Europe’s health sector under its TechEU programme.
EU Commission presents new bioeconomy strategy
Latest NewsA month after China publicly revealed its bioeconomy priorities under its 15th Five Year Plan, the European Commission released an updated EU Bioeconomy Strategy — and the contrast could hardly be sharper. While China bets on a bold mix of AI, bioengineering and synthetic biology to replace fossil based industrial products with recombinant and cell free systems, the EU remains anchored in a more traditional vision focused on the valorisation of agricultural output and industrial waste. By contrast, the UK has taken a more modern approach, heavily investing in engineering biology — the use of reprogrammed microorganisms to produce industrial goods — as a key pillar of its biotech and bioeconomy strategy.
€ 23 Mio: Afyren successful in capital increase
Latest NewsFrench Afyren secures €23m to accelerate biorefinery expansion as first plant enters full industrial ramp-up. Most of the money comes from US company Kemin Industries.
Ventuno Biotech Secures €3m to Power Next-Gen Cancer Immunotherapies
Latest NewsLyon-based Ventuno Biotech secures fresh backing to accelerate its preclinical pipeline of first-in-class immuno-oncology assets.
Novo Nordisk’s semaglutide fails in Alzheimer’s
Latest NewsNovo Nordisk’s semaglutide has failed to reduce the cognition deficit in two Phase III Alzheimer’s trials, dimming GLP-1 hopes. Anti-amyloid and combination therapies remain key for slowing decline.
Gilead acquires Sprint Bioscience TREX1 programme
Latest NewsSprint Bioscience AB has sold its preclinical TREX1 first-in-class cancer program to Gilead for up to US$414m, validating its fragment-driven small-molecule out-licensing business model.